We examined the efficacy of long-term subcutaneous deferoxamine therapy in the prevention of iron-related cardiac disease in patients with thalassemia major who began treatment after the age of 10 years. Of 36 such patients without preexisting cardiac disease, 19 did not comply with the program of chelation therapy. Over the course of treatment (1977 to 1983) serum ferritin and aspartate aminotransferase levels fell in the compliant group, from mean values (+/- S.D.) of 4765 +/- 2610 to 2950 +/- 1850 ng per milliliter and 58.1 +/- 22 IU to 30 +/- 20 IU per liter, respectively (P less than 0.05), but rose in the noncompliant group, from 5000 +/- 2316 to 6040 +/- 2550 ng per milliliter and 56.6 +/- 20 to 90 +/- 35 IU per liter, respectively. Only one patient in the compliant group acquired cardiac disease and died of fulminant congestive heart failure. In contrast, 12 noncompliant patients acquired cardiac disease, and 7 died. In addition, the mean age of the compliant population (18.9 +/- 4.5 years) now approaches the mean age of acquisition of cardiac disease in the noncompliant group (19 +/- 4.3). These data demonstrate that compliance with treatment with deferoxamine may protect patients from cardiac disease induced by iron overload.
This article has been cited by other articles:
Walker, E. M. Jr., Morrison, R. G., Dornon, L., Laurino, J. P., Walker, S. M., Studeny, M., Wehner, P. S., Rice, K. M., Wu, M., Blough, E. R.
(2009). Acetaminophen Combinations Protect Against Iron-Induced Cardiac Damage in Gerbils. Annals of Clinical & Laboratory Science
39: 378-385
[Abstract][Full Text]
Silvilairat, S., Sittiwangkul, R., Pongprot, Y., Charoenkwan, P., Phornphutkul, C.
(2008). Tissue Doppler echocardiography reliably reflects severity of iron overload in pediatric patients with {beta} thalassemia. Eur J Echocardiogr
9: 368-372
[Abstract][Full Text]
Bloomer, S. A., Brown, K. E., Buettner, G. R., Kregel, K. C.
(2008). Dysregulation of hepatic iron with aging: implications for heat stress-induced oxidative liver injury. Am. J. Physiol. Regul. Integr. Comp. Physiol.
294: R1165-R1174
[Abstract][Full Text]
Tefferi, A.
(2007). Primary myelofibrosis and its paraneoplastic stromal effects. haematol
92: 577-579
[Full Text]
Glickstein, H., El, R. B., Link, G., Breuer, W., Konijn, A. M., Hershko, C., Nick, H., Cabantchik, Z. I.
(2006). Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood
108: 3195-3203
[Abstract][Full Text]
Pennell, D. J., Berdoukas, V., Karagiorga, M., Ladis, V., Piga, A., Aessopos, A., Gotsis, E. D., Tanner, M. A., Smith, G. C., Westwood, M. A., Wonke, B., Galanello, R.
(2006). Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood
107: 3738-3744
[Abstract][Full Text]
Cappellini, M. D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., Aydinok, Y., Kattamis, A., Kilinc, Y., Porter, J., Capra, M., Galanello, R., Fattoum, S., Drelichman, G., Magnano, C., Verissimo, M., Athanassiou-Metaxa, M., Giardina, P., Kourakli-Symeonidis, A., Janka-Schaub, G., Coates, T., Vermylen, C., Olivieri, N., Thuret, I., Opitz, H., Ressayre-Djaffer, C., Marks, P., Alberti, D.
(2006). A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood
107: 3455-3462
[Abstract][Full Text]
Bosi, G, Crepaz, R, Gamberini, M R, Fortini, M, Scarcia, S, Bonsante, E, Pitscheider, W, Vaccari, M
(2003). Left ventricular remodelling, and systolic and diastolic function in young adults with {beta} thalassaemia major: a Doppler echocardiographic assessment and correlation with haematological data. Heart
89: 762-766
[Abstract][Full Text]
Nathan, D. G., Weatherall, D. J.
(2002). Academic Freedom in Clinical Research. NEJM
347: 1368-1371
[Full Text]
Bergeron, R. J., Wiegand, J., Brittenham, G. M.
(2002). HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood
99: 3019-3026
[Abstract][Full Text]
Walker, J. M.
(2002). The heart in thalassaemia. Eur Heart J
23: 102-105
[Full Text]
Kushner, J. P., Porter, J. P., Olivieri, N. F.
(2001). Secondary Iron Overload. ASH Education Book
2001: 47-61
[Abstract][Full Text]
Kuryshev, Y. A., Brittenham, G. M., Fujioka, H., Kannan, P., Shieh, C.-C., Cohen, S. A., Brown, A. M.
(1999). Decreased Sodium and Increased Transient Outward Potassium Currents in Iron-Loaded Cardiac Myocytes : Implications for the Arrhythmogenesis of Human Siderotic Heart Disease. Circulation
100: 675-683
[Abstract][Full Text]
Olivieri, N. F.
(1999). The {beta}-Thalassemias. NEJM
341: 99-109
[Full Text]
Tsushima, R. G., Wickenden, A. D., Bouchard, R. A., Oudit, G. Y., Liu, P. P., Backx, P. H.
(1999). Modulation of Iron Uptake in Heart by L-Type Ca2+ Channel Modifiers : Possible Implications in Iron Overload. Circ. Res.
84: 1302-1309
[Abstract][Full Text]
Horwitz, L. D, Rosenthal, E. A
(1999). Iron-mediated cardiovascular injury. Vasc Med
4: 93-99
[Abstract]
Bergeron, R. J., Wiegand, J., Brittenham, G. M.
(1999). HBED: The Continuing Development of a Potential Alternative to Deferoxamine for Iron-Chelating Therapy. Blood
93: 370-375
[Abstract][Full Text]
Economou-Petersen, E., Aessopos, A., Kladi, A., Flevari, P., Karabatsos, F., Fragodimitri, C., Nicolaidis, P., Vrettou, H., Vassilopoulos, D., Karagiorga-Lagana, M., Kremastinos, D. Th., Petersen, M. B.
(1998). Apolipoprotein E &b.epsi;4 Allele as a Genetic Risk Factor for Left Ventricular Failure in Homozygous beta -Thalassemia. Blood
92: 3455-3459
[Abstract][Full Text]
Rivkin, G., Link, G., Simhon, E., Cyjon, R. L., Klein, J. Y., Hershko, C.
(1997). IRC011, a New Synthetic Chelator With Selective Interaction With Catabolic Red Blood Cell Iron: Evaluation in Hypertransfused Rats With Hepatocellular and Reticuloendothelial Radioiron Probes and in Iron-Loaded Rat Heart Cells in Culture. Blood
90: 4180-4187
[Abstract][Full Text]
Olivieri, N. F., Brittenham, G. M.
(1997). Iron-Chelating Therapy and the Treatment of Thalassemia. Blood
89: 739-761
[Full Text]
Olivieri, N. F., Brittenham, G. M., Matsui, D., Berkovitch, M., Blendis, L. M., Cameron, R. G., McClelland, R. A., Liu, P. P., Templeton, D. M., Koren, G.
(1995). Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major. NEJM
332: 918-922
[Abstract][Full Text]
Brittenham, G. M., Griffith, P. M., Nienhuis, A. W., McLaren, C. E., Young, N. S., Tucker, E. E., Allen, C. J., Farrell, D. E., Harris, J. W.
(1994). Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major. NEJM
331: 567-573
[Abstract][Full Text]
Olivieri, N. F., Nathan, D. G., MacMillan, J. H., Wayne, A. S., Liu, P. P., McGee, A., Martin, M., Koren, G., Cohen, A. R.
(1994). Survival in Medically Treated Patients with Homozygous {beta}-Thalassemia. NEJM
331: 574-578
[Abstract][Full Text]
Hou, J.-W., Wu, M.-H., Lin, K.-H., Lue, H.-C.
(1994). Prognostic Significance of Left Ventricular Diastolic Indexes in {beta}-Thalassemia Major. Arch Pediatr Adolesc Med
148: 862-866
[Abstract]
Olivieri, N. F., Liu, P. P., Sher, G. D., Daly, P. A., Greig, P. D., McCusker, P. J., Collins, A. F., Francombe, W. H., Templeton, D. M., Butany, J.
(1994). Combined Liver and Heart Transplantation for End-Stage Iron-Induced Organ Failure in an Adult with Homozygous Beta-Thalassemia. NEJM
330: 1125-1128
[Full Text]
Lowrey, C. H., Nienhuis, A. W.
(1993). Treatment with Azacitidine of Patients with End-Stage {beta}-Thalassemia. NEJM
329: 845-848
[Full Text]
Maurer, H. S., Lloyd-Still, J. D., Ingrisano, C., Gonzalez-Crussi, F., Honig, G. R.
(1988). A Prospective Evaluation of Iron Chelation Therapy in Children With Severe {beta}-Thalassemia: A Six-Year Study. Arch Pediatr Adolesc Med
142: 287-292
[Abstract]
Sklar, C. A., Lew, L. Q., Yoon, D. J., David, R.
(1987). Adrenal Function in Thalassemia Major Following Long-term Treatment With Multiple Transfusions and Chelation Therapy: Evidence for Dissociation of Cortisol and Adrenal Androgen Secretion. Arch Pediatr Adolesc Med
141: 327-330
[Abstract]
Grisaru, D., Goldfarb, A. W., Gotsman, M. S., Rachmilewitz, E. A., Hasin, Y.
(1986). Deferoxamine Improves Left Ventricular Function in {beta}-Thalassemia. Arch Intern Med
146: 2344-2349
[Abstract]
KANZ, L., ARNOLD, H., LOHR, G.W.
(1986). High-Dose Desferoxamine and Diamond-Blackfan Anemia. ANN INTERN MED
104: 585-586
[Abstract]
Previous
